Filtered By:
Cancer: Neuroblastoma

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 288 results found since Jan 2013.

NICOTINAMIDE N-METHYLTRANSFERASE increases complex I activity IN SH-SY5Y cells via SIRTUIN-3.
Abstract Nicotinamide N-methyltransferase (NNMT, E.C. 2.1.1.1) N-methylates nicotinamide to 1-methylnicotinamide. We have previously shown that NNMT is significantly overexpressed in the brains of patients who have died of Parkinson's disease, and others have shown that NNMT is significantly overexpressed in a variety of diseases ranging from cancer to hepatic cirrhosis. In vitro overexpression has revealed many cytoprotective effects of NNMT, in particular increased complex I activity and ATP synthesis. Although this appears to be mediated by an increase in 1-methylnicotinamide production, the molecular mechanism...
Source: Biochemical and Biophysical Research communications - October 8, 2015 Category: Biochemistry Authors: Liu KY, Mistry RJ, Aguirre CA, Fasouli ES, Thomas MG, Klamt F, Ramsden DB, Parsons RB Tags: Biochem Biophys Res Commun Source Type: research

Mitogen-activated protein kinases regulate expression of neuronal nitric oxide synthase and neurite outgrowth via non-classical retinoic acid receptor signaling in human neuroblastoma SH-SY5Y cells
Publication date: Available online 11 September 2015 Source:Journal of Pharmacological Sciences Author(s): Tatsuya Fujibayashi, Yuki Kurauchi, Akinori Hisatsune, Takahiro Seki, Koichi Shudo, Hiroshi Katsuki We have previously shown that retinoic acid receptor (RAR) stimulation by an agonist Am80 recruits nitric oxide-dependent signaling via increased expression of neuronal nitric oxide synthase (nNOS) in rat midbrain slice cultures. Using neuroblastoma SH-SY5Y cells, here we investigated the mechanisms of RAR-induced nNOS expression, together with relationship between nNOS expression and neurite outgrowth. Am80 pro...
Source: Journal of Pharmacological Sciences - September 12, 2015 Category: Drugs & Pharmacology Source Type: research

Elevation of Sestrin-2 expression attenuates Sevoflurane induced neurotoxicity
In this study, our results indicated that administration of Sevoflurane elevated the gene and protein expression of Sestrin-2 in a dose dependent manner in human neuroblastoma M17 cells. It was shown that silence of Sestrin-2 by small RNA interference (siRNA) ominously exacerbated the increase in intracellular ROS and reduction of SOD activity induced by Sevoflurane treatment. Notably, knockdown of Sestrin-2 in M17 cells significantly increases the number of apoptotic cells after treatment with Sevoflurane. Mechanistically, we also found that Sevoflurane treatment resulted in a reduced amount of the cytosolic anti-apoptoti...
Source: Metabolic Brain Disease - September 5, 2015 Category: Neurology Source Type: research

New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Authors: Di Paolo D, Yang D, Pastorino F, Emionite L, Cilli M, Daga A, Destefanis E, Di Fiore A, Piaggio F, Brignole C, Xu X, Liang C, Gibbons J, Ponzoni M, Perri P Abstract Many different aberrations in the Anaplastic Lymphoma Kinase (ALK) were found to be oncogenic drivers in several cancers including neuroblastoma (NB), therefore ALK is now considered a critical player in NB oncogenesis and a promising therapeutic target. The ALK-inhibitor crizotinib has a limited activity against the various ALK mutations identified in NB patients. We tested: the activity of the novel ALK-inhibitor X-396 administered alone or i...
Source: Oncotarget - August 26, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Melatonin attenuates methamphetamine-induced neuroinflammation through the melatonin receptor in the SH-SY5Y cell line.
In this study, we investigated the effect of methamphetamine on TNFα expression and NFκB activation in the neuroblastoma cell line SH-SY5Y. We demonstrated the time-dependent effect of methamphetamine on the induction of TNFα expression as well as IκB degradation and NFκB nuclear translocation. Furthermore, we investigated the effect of melatonin on methamphetamine-induced TNFα overexpression and NFκB activation. The results showed that pretreatment with 100nM melatonin could prevent the TNFα overexpression caused by methamphetamine exposure. This attenuating effect was prevented by pre-incubation with luzindole, a...
Source: Neurotoxicology - August 14, 2015 Category: Neurology Authors: Wongprayoon P, Govitrapong P Tags: Neurotoxicology Source Type: research

Abstract 5431: Polysialyltransferase ST8SiaII: A novel target for the treatment of neuroblastoma
Polysialic acid (polySia) is a carbohydrate polymer expressed on the surface of NCAM (neuronal cell adhesion molecule) in many cancer cells where it modulates cell-cell and cell-matrix adhesion, migration, invasion and metastasis. PolySia expression is strongly associated with poor clinical prognosis and correlates with aggressive/invasive disease in neuroblastoma and many other tumours principally of neuroendocrine origin [1]. SiRNA knockdown of polysialyltransferase ST8SiaII, the enzyme primarily responsible for polySia synthesis in tumours, has been shown to abolish tumour cell migration [2]. Besides brain regions with ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Elkashef, S. M., Viprey, V., Saeed, R. F., Springett, B. R., Sutherland, M., Loadman, P. M., Patterson, L. H., Shnyder, S. D., Falconer, R. A. Tags: Experimental and Molecular Therapeutics Source Type: research

Abstract 5213: RUNX2 modulates the angiogenic potential of human neuroblastoma cells
In conclusion, our study suggests that hypoxia upregulates RUNX2 expression in NB1691 cells and knockdown of RUNX2 decreases the angiogenic potential of hypoxic NB1691 cells.Citation Format: Manu Gnanamony, Indra Mohanam, Sanjeeva Mohanam. RUNX2 modulates the angiogenic potential of human neuroblastoma cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5213. doi:10.1158/1538-7445.AM2015-5213
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Gnanamony, M., Mohanam, I., Mohanam, S. Tags: Tumor Biology Source Type: research

Abstract 144: CASC15 is a tumor suppressor lncRNA at the 6p22 neuroblastoma susceptibility locus
Background: Neuroblastoma, a clinically heterogeneous childhood tumor, presents as high-risk disease in 40% of diagnoses and is fatal in roughly half of these patients. In an effort to elucidate the genetic basis of high-risk disease, our lab previously undertook a genome-wide association study (2101 cases, 4202 controls), identifying a cluster of single-nucleotide polymorphisms on chromosome 6p associate with an increased risk of developing of high-risk disease (p
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Russell, M. R., Penikis, A., Oldridge, D., Alvarez-Dominguez, J. R., McDaniel, L., Diamond, M., Padovan, O., Raman, P., Li, Y., Wei, J., Zhang, S., Gnanachandran, J., Seeger, R., Asgharzadeh, S., Khan, J., Diskin, S., Maris, J., Cole, K. Tags: Molecular and Cellular Biology Source Type: research

Abstract 146: The long noncoding RNA MALAT1 promotes hypoxia-driven angiogenesis by upregulating pro-angiogenic gene expression in neuroblastoma cells
Neuroblastoma is the most common solid tumour during early childhood, and accounts for 15% of all childhood cancer death. One of the key features of neuroblastoma is aggressive progression due to tumour-driven angiogenesis. However, the mechanism through which neuroblastoma cells drive angiogenesis is unclear. Here we showed that the long noncoding RNA MALAT1 was over-expressed in human neuroblastoma cells under hypoxic condition, the condition which triggers pro-angiogenic switch and angiogenesis. In vitro angiogenesis assays demonstrated that conditioned medium from neuroblastoma cells transfected with MALAT1 siRNAs, com...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Tee, A. E., Liu, P., Maag, J., Song, R., Li, J., Cheung, B. B., Haber, M., Norris, M. D., Marshall, G. M., Dinger, M., Liu, T. Tags: Molecular and Cellular Biology Source Type: research

Abstract 3266: Inhibition of Rho-associated kinase 2 suppresses MYCN expression and induces differentiation of neuroblastoma
Conclusions: Our results show the significance of the non-canonical/PCP signaling cascade in neuroblastoma development and progression. Furthermore, ROCK inhibition suppress the growth of neuroblastoma in preclinical models and provide a novel option for improved treatment of high-risk neuroblastoma.Citation Format: Cecilia Dyberg, David Forsberg, Susanne Fransson, Jessika Lännerholm Palm, Bjorn Helge Haug, Baldur Sveinbjornsson, Tommy Martinsson, Per Kogner, John Inge Johnsen, Malin Wickstrom. Inhibition of Rho-associated kinase 2 suppresses MYCN expression and induces differentiation of neuroblastoma. [abstract]. In: Pr...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Dyberg, C., Forsberg, D., Fransson, S., Lannerholm Palm, J., Haug, B. H., Sveinbȷornsson, B., Martinsson, T., Kogner, P., Johnsen, J. I., Wickstrom, M. Tags: Tumor Biology Source Type: research

Abstract 475: Identification of SHANK2 as a tumor suppressor disrupted by recurrent somatic structural variation (SV) in neuroblastoma
Background. Neuroblastoma is a malignancy of the developing sympathetic nervous system which exacts significant morbidity and mortality in children. Large sequencing efforts have revealed a relative paucity of somatic point mutations in this and other childhood cancers. Structural variations (SVs) including translocations, inversions, deletions, duplications, and other complex events can occur in germline DNA or be acquired somatically in tumors. Recurrent somatic SVs affecting known genes are likely to be functional and may elucidate novel tumor suppressors or oncogenes.Methods. We are performing whole-genome sequencing (...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Conkrite, K., Ferraro, N., McDaniel, L., Oldridge, D. A., Attiyeh, E., Asgharzadeh, S., Diamond, M., Guidry Auvil, J., Davidsen, T., Smith, M., London, W. B., Seeger, R., Khan, J., Gerhard, D. S., Maris, J. M., Diskin, S. J. Tags: Tumor Biology Source Type: research

Abstract 487: Whole genome screen to identify genes targeting MYCN-driven embryonal tumors
MYCN is a driver of neuroblastoma (NB) tumorigenesis and is over-expressed in a number of tumors of embryonal origin, including rhabdomyosarcoma, medulloblastoma and diffuse intrinsic pontine gliomas. We sought to identify regulators of MYCN transcription by performing a whole genome screen (WGS) for regulators of MYCN promoter activity using a NB cell model. A plasmid containing the MYCN promoter (1.3kb upstream of MYCN TSS) fused to luciferase and stably integrated into the genome of NGP NB cells was the readout system. NGP-MYCNpluc, was selected based on MYCN luciferase activity inhibition by ATRA and HDAC inhibitors to...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Thiele, C. J., Liu, Z., Veschi, V., Buehler, E., Martin, S. Tags: Tumor Biology Source Type: research

Abstract LB-290: Multiple distinct mechanisms disrupt let-7 miRNA biogenesis and function in neuroblastoma
The let-7 microRNA family are known tumor suppressors often deregulated in cancer, yet the underlying mechanisms of let-7 disruption remain poorly understood. Neuroblastoma, a neural crest derived tumor, is defined in part by poor prognosis associated with genetic amplification of MYCN, itself a let-7 target. The let-7 biogenesis inhibitor LIN28B has recently been implicated as a critical regulator of MYCN, but we have employed siRNA and CRISPR-mediated gene disruption to show that LIN28B is dispensable for both MYCN protein expression and growth of MYCN-amplified neuroblastoma cell lines despite robust de-repression of le...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Powers, J. T., Tsanov, K. M., Roles, F., Ebright, R., Seligson, M., de Soysa, Y., Cahan, P., Theissen, J., LaPier, G. S., Pearson, D. S., Berthold, F., Daley, G. Q. Tags: Molecular and Cellular Biology Source Type: research

Abstract 191: The role of microRNAs in the epigenetic silencing of CHD5, a tumor suppressor in neuroblastoma
Background: Neuroblastoma (NB) is a tumor of the sympathetic nervous system that is the most common extracranial solid tumor of childhood. NBs show remarkable clinical heterogeneity, and we, along with others, have identified different patterns of genomic change that underlie these diverse clinical behaviors. We first identified 1p deletion as a characteristic change in advanced stage NBs. CHD5, a tumor suppressor gene, was first identified because of its location on 1p36. However, mutation of the remaining allele of CHD5 is rare in these tumors. Therefore, it is likely that epigenetic mechanisms play important roles in CH...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Naraparaju, K., Kolla, V., Zhuang, T., Higashi, M., Blobel, G. A., Brodeur, G. M. Tags: Molecular and Cellular Biology Source Type: research

Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
Conclusion: Selective inhibition of CDK4/6 using palbociclib may provide a new therapeutic option for treating neuroblastoma.
Source: Cancer Cell International - July 30, 2015 Category: Cancer & Oncology Authors: Ali RihaniJo VandesompeleFrank SpelemanTom Van Maerken Source Type: research